303 related articles for article (PubMed ID: 21527517)
1. A CK2-dependent mechanism for activation of the JAK-STAT signaling pathway.
Zheng Y; Qin H; Frank SJ; Deng L; Litchfield DW; Tefferi A; Pardanani A; Lin FT; Li J; Sha B; Benveniste EN
Blood; 2011 Jul; 118(1):156-66. PubMed ID: 21527517
[TBL] [Abstract][Full Text] [Related]
2. CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients.
Pardanani A; Lasho T; Smith G; Burns CJ; Fantino E; Tefferi A
Leukemia; 2009 Aug; 23(8):1441-5. PubMed ID: 19295546
[TBL] [Abstract][Full Text] [Related]
3. Combined inhibition of Janus kinase 1/2 for the treatment of JAK2V617F-driven neoplasms: selective effects on mutant cells and improvements in measures of disease severity.
Liu PC; Caulder E; Li J; Waeltz P; Margulis A; Wynn R; Becker-Pasha M; Li Y; Crowgey E; Hollis G; Haley P; Sparks RB; Combs AP; Rodgers JD; Burn TC; Vaddi K; Fridman JS
Clin Cancer Res; 2009 Nov; 15(22):6891-900. PubMed ID: 19887489
[TBL] [Abstract][Full Text] [Related]
4. JAKs, Stats, and CK2?
Carter-Su C; Argetsinger LS
Blood; 2011 Jul; 118(1):5-6. PubMed ID: 21737607
[No Abstract] [Full Text] [Related]
5. JAK/STAT signal transduction: regulators and implication in hematological malignancies.
Valentino L; Pierre J
Biochem Pharmacol; 2006 Mar; 71(6):713-21. PubMed ID: 16426581
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of protein kinase II (CK2) prevents induced signal transducer and activator of transcription (STAT) 1/3 and constitutive STAT3 activation.
Aparicio-Siegmund S; Sommer J; Monhasery N; Schwanbeck R; Keil E; Finkenstädt D; Pfeffer K; Rose-John S; Scheller J; Garbers C
Oncotarget; 2014 Apr; 5(8):2131-48. PubMed ID: 24742922
[TBL] [Abstract][Full Text] [Related]
7. JAK2V617F-negative ET patients do not display constitutively active JAK/STAT signaling.
Schwemmers S; Will B; Waller CF; Abdulkarim K; Johansson P; Andreasson B; Pahl HL
Exp Hematol; 2007 Nov; 35(11):1695-703. PubMed ID: 17764814
[TBL] [Abstract][Full Text] [Related]
8. The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms.
Hobbs GS; Rozelle S; Mullally A
Hematol Oncol Clin North Am; 2017 Aug; 31(4):613-626. PubMed ID: 28673391
[TBL] [Abstract][Full Text] [Related]
9. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.
Pikman Y; Lee BH; Mercher T; McDowell E; Ebert BL; Gozo M; Cuker A; Wernig G; Moore S; Galinsky I; DeAngelo DJ; Clark JJ; Lee SJ; Golub TR; Wadleigh M; Gilliland DG; Levine RL
PLoS Med; 2006 Jul; 3(7):e270. PubMed ID: 16834459
[TBL] [Abstract][Full Text] [Related]
10. TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.
Pardanani A; Hood J; Lasho T; Levine RL; Martin MB; Noronha G; Finke C; Mak CC; Mesa R; Zhu H; Soll R; Gilliland DG; Tefferi A
Leukemia; 2007 Aug; 21(8):1658-68. PubMed ID: 17541402
[TBL] [Abstract][Full Text] [Related]
11. Recent patents of gene mutation relative to JAK/STAT pathway and their implication in myeloproliferative diseases.
Shi Y; Xu C
Recent Pat DNA Gene Seq; 2008; 2(3):209-13. PubMed ID: 19075958
[TBL] [Abstract][Full Text] [Related]
12. Role of JAK-STAT signaling in the pathogenesis of myeloproliferative disorders.
Levine RL; Wernig G
Hematology Am Soc Hematol Educ Program; 2006; ():233-9, 510. PubMed ID: 17124066
[TBL] [Abstract][Full Text] [Related]
13. JAKs go nuclear: emerging role of nuclear JAK1 and JAK2 in gene expression and cell growth.
Zouein FA; Duhé RJ; Booz GW
Growth Factors; 2011 Dec; 29(6):245-52. PubMed ID: 21892841
[TBL] [Abstract][Full Text] [Related]
14. JAK/STAT signaling in hematological malignancies.
Vainchenker W; Constantinescu SN
Oncogene; 2013 May; 32(21):2601-13. PubMed ID: 22869151
[TBL] [Abstract][Full Text] [Related]
15. Crizotinib Has Preclinical Efficacy in Philadelphia-Negative Myeloproliferative Neoplasms.
Gurska LM; Okabe R; Schurer A; Tong MM; Soto M; Choi D; Ames K; Glushakow-Smith S; Montoya A; Tein E; Miles LA; Cheng H; Hankey-Giblin P; Levine RL; Goel S; Halmos B; Gritsman K
Clin Cancer Res; 2023 Mar; 29(5):943-956. PubMed ID: 36537918
[TBL] [Abstract][Full Text] [Related]
16. Is there a role for JAK inhibitors in BCR-ABL1-negative myeloproliferative neoplasms other than myelofibrosis?
Pardanani A; Tefferi A
Leuk Lymphoma; 2014 Dec; 55(12):2706-11. PubMed ID: 25520049
[TBL] [Abstract][Full Text] [Related]
17. [Negative regulation of the JAK/STAT: pathway implication in tumorigenesis].
Espert L; Dusanter-Fourt I; Chelbi-Alix MK
Bull Cancer; 2005 Oct; 92(10):845-57. PubMed ID: 16266868
[TBL] [Abstract][Full Text] [Related]
18. JAK2 inhibitors in the treatment of myeloproliferative neoplasms.
Tibes R; Bogenberger JM; Geyer HL; Mesa RA
Expert Opin Investig Drugs; 2012 Dec; 21(12):1755-74. PubMed ID: 22991927
[TBL] [Abstract][Full Text] [Related]
19. Anti-inflammatory cytokines hepatocyte growth factor and interleukin-11 are over-expressed in Polycythemia vera and contribute to the growth of clonal erythroblasts independently of JAK2V617F.
Boissinot M; Cleyrat C; Vilaine M; Jacques Y; Corre I; Hermouet S
Oncogene; 2011 Feb; 30(8):990-1001. PubMed ID: 21042281
[TBL] [Abstract][Full Text] [Related]
20. The JAK-inhibitor, JAB/SOCS-1 selectively inhibits cytokine-induced, but not v-Src induced JAK-STAT activation.
Iwamoto T; Senga T; Naito Y; Matsuda S; Miyake Y; Yoshimura A; Hamaguchi M
Oncogene; 2000 Sep; 19(41):4795-801. PubMed ID: 11032030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
